Key features and details
- Potent EGFR tyrosine kinase inhibitor
- CAS Number: 183319-69-9
- Purity: > 98%
- Soluble in DMSO to 25 mM (with warming)
- Form / State: Solid
- Source: Synthetic
Product nameErlotinib hydrochloride, EGFR tyrosine kinase inhibitor
DescriptionPotent EGFR tyrosine kinase inhibitor
- Erlotinib HCl
Potent EGFR tyrosine kinase inhibitor (IC50 = 2 nM). Decreases EGFR autophosphorylation in tumor cells. Potent inhibitor of mutant JAK2-V617F. Weaker inhibitor of ErbB-2 kinase (Ki = 1 μM) and ErbB-4 kinase (Ki = 1.5 μM). Clinically effective agent for non-small cell lung cancer (NSCLC).
Chemical nameN-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride
Storage instructionsShipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
Solubility overviewSoluble in DMSO to 25 mM (with warming)
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab141930 has been referenced in 4 publications.
- Gan CJ et al. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation. Biochem Biophys Rep 22:100763 (2020). PubMed: 32322693
- Stahlhut C & Slack FJ Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle 14:2171-80 (2015). PubMed: 25714397
- Vu TH et al. Depsides: lichen metabolites active against hepatitis C virus. PLoS One 10:e0120405 (2015). PubMed: 25793970
- Nishimura T et al. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. BMC Cancer 15:957 (2015). PubMed: 26673416